Why Supernus Pharmaceuticals Stock Is On Investors’ Radar This Week

Supernus Pharmaceuticals (SUPN) has drawn fresh attention after releasing fourth quarter and full year 2025 results alongside new 2026 guidance that pairs higher revenue expectations with a relatively modest operating earnings range.

Those 2025 results and the fresh 2026 guidance arrived after a strong 12 months for investors, with a 1 year total shareholder return of 67.98% and a 5 year total shareholder return of 101.72%. The 30 day and 90 day share price returns of 9.76% and 17.93% suggest momentum has recently been building, despite a softer 1 day and 7 day share price pullback around the latest earnings and guidance headlines.

If you are looking beyond a single CNS focused name, this could be a useful moment to scan other healthcare related opportunities using our screener of 32 healthcare AI stocks as a starting shortlist.

With Supernus shares up sharply over the past year, yet still trading below the average analyst price target and an implied intrinsic value, the key question is whether there is still a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 12.2% Undervalued

Supernus Pharmaceuticals’ most followed valuation narrative puts fair value at $61.33 per share, versus the latest close of $53.87, suggesting upside that the market has not fully reflected.

Expanding patient pool for core products, Qelbree and GOCOVRI, driven by increased prevalence and diagnosis of CNS disorders, as well as broader healthcare access (especially among Medicare patients, as seen with GOCOVRI’s prescription growth), is likely to sustain robust top-line revenue growth.

Commercial infrastructure and recent launch of ONAPGO position Supernus to capture further market share in Parkinson’s disease, benefiting from demographic aging and rising CNS disease burden, which should materially boost revenue and improve gross margins as fixed costs are leveraged.

Want to understand why this fair value sits well above today’s price? The narrative leans on brisk revenue expansion, shifting margins, and a richer earnings profile shaped by future CNS launches. The tension lies in how those cash flows are discounted at 6.98% and what kind of earnings multiple that path could justify by itself.

Result: Fair Value of $61.33 (UNDERVALUED)

However, this story still carries risk, particularly around rising SG&A and R&D costs, as well as Supernus’ heavy dependence on a handful of CNS products.

Another Angle On Valuation

The fair value narrative points to upside, but the current P/S of 4.3x tells a slightly different story. It sits in line with the wider US Pharmaceuticals group at 4.3x, yet below a fair ratio of 7.1x and the 15.4x peer average. Is the market being cautious or just early?

Next Steps

The sentiment so far has been cautiously optimistic. If the story interests you, consider acting while the details are fresh and weigh the potential benefits against the risks by checking the 2 key rewards for yourself.

Looking For More Investment Ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock. Use the tools available and keep your opportunity set wide.

• Spot potential value opportunities early by scanning our list of 50 high quality undervalued stocks that currently stand out on fundamentals.
• Prioritise resilience by reviewing a curated group of companies in the 63 resilient stocks with low risk scores that score well on our risk metrics.
• Hunt for underfollowed opportunities by checking the screener containing 24 high quality undiscovered gems that combine quality traits with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.